Influenza prevention and treatment - An update

Pharmaceutical Journal

Volumn 265, Issue 7115, 2000, Pages 446-451

  Elliot, A ^a   Ellis, J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 (1 ACETAMIDO 2 ETHYLBUTYL) 4C GUANIDINO 2 HYDROXYCYCLOPENTANE 1 CARBOXYLIC ACID; AMANTADINE; FLUMAVINE; INFLUENZA VACCINE; OSELTAMIVIR; RIMANTADINE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; IMMUNIZATION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; MORBIDITY; MORTALITY; OTITIS MEDIA; PALLIATIVE THERAPY; RESPIRATORY TRACT INFECTION; REVIEW;

EID: 0034706221     PISSN: 00316873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. The impact of three influenza epidemics on primary care in England and Wales
2. Human influenza
3. Evaluation of a rapid immunoassay for the detection of influenza A virus
4. Comparison of rapid immunofluorescence procedure with test pack RSV and directigen flu A for diagnosis of respiratory syncytial virus and influenza A virus
5. Comparison of directigen flu-A with viral isolation and direct immunofluorescence for the rapid detection and identification of influenza A virus
6. A revision of the system of nomenclature for influenza viruses: A WHO memorandum
7. Antigenic analysis of influenza A surface antigens. Considerations for the nomenclature of influenza virus
8. Characterisation of a novel influenza haemagglutinin, H15; criteria for determination of influenza A subtypes
9. The Tecumesh study of illness. XIII. Influenza infection and disease, 1976-81
10. Pandemic variation of influenza viruses
11. WHO influenza surveillance
12. Recommendations for influenza vaccine composition for use in 2000-2001
13. Influenza vaccine uptake and distribution in England and Wales, July 1989-June 1997
14. Effectiveness of influenza vaccination policy at targeting patients at high risk of complications during winter 1994-5: Cross sectional survey
15. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children
16. Use of live attenuated cold-adapted influenza A reassortant virus vaccines in infants, children, young adults and elderly adults
17. Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A
18. Amantadine and rimantadine
19. Rimantadine prophylaxis in children: A follow-up study
20. Safety and prophylactic efficacy of low-dose rimantadine in adults during an influenza A epidemic
21. The roles of vaccination and amantadine prophylaxis in controlling an outbreak of influenza A (H3N2) in a nursing home
22. Influenza A prophylaxis with amantadine in a boarding school
23. Recovery of drug-resistant influenza A virus during therapeutic use of rimantidine
24. Children with influenza A infection: Treatment with rimantadine
25. Antiviral agents to prevents or treat influenza in the elderly
26. Genetic basis of resistance to rimantidine emerging treatment of influenza virus infection
27. The action af adamantanamines against influenza A viruses: Inhibition of the M2 ion channel protein
28. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families
29. Resistance of influenza A virus to amantadine and rimantadines: Results of one decade of surveillance
30. Rational design of potent sialidase-based inhibitors of influenza virus replication
31. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: A randomised, double-blind, placebo-controlled European study
32. Efficacy and safety of the neuramidase inhibitor zanamivir in the treatment of influenza A and B virus infections
33. Zanamivir in the prevention of influenza among healthy adults: A randomised controlled trial
34. Safety and efficacy of neuraminidase inhibitor GG167 in experimental human influenza
35. Efficacy and safety of the neuraminidase zanamivir in the treatment of influenza virus infections
36. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections
37. New influenza theraphy voted down by the FDA panellists
38. NICE's guidance on the use of zanamivir (Relenza) for the treatment of influenza
39. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: Design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity
40. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: Randomised controlled trials for prevention and treatment
41. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza
42. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection
43. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomised controlled trial
44. Efficacy and safety of oseltamivir in treatment of acute influenza: A randomised controlled trial